首页> 外文期刊>The American journal of hospice and palliative care >Oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients: an overview of its pharmacological and clinical characteristics.
【24h】

Oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients: an overview of its pharmacological and clinical characteristics.

机译:口服粘膜柠檬酸芬太尼用于治疗癌症患者的突破性疼痛:其药理和临床特征概述。

获取原文
获取原文并翻译 | 示例
           

摘要

Breakthrough pain is a transitory flare of pain occurring in most cancer patients against a background of otherwise controlled persistent pain. Treatment of breakthrough pain is a challenging phenomenon. Oral transmucosal fentanyl citrate (Actiq, Cephalon, Inc, West Chester, PA), a new opioid formulation with a unique delivery system, reflects the characteristics of breakthrough pain (rapid onset of action and short duration), making it an effective treatment for cancer patients who already receive opioids and experience flares of pain. This review article aims to present the role of oral transmucosal fentanyl citrate in the management of breakthrough pain in cancer patients. In particular, it is going to discuss the synthesis, clinical pharmacology, pharmacokinetic and pharmacodynamic properties, toxicity, and clinical efficacy of this novel agent.
机译:突破性疼痛是在大多数癌症患者中发生的短暂疼痛发作,其背景是本来可以控制的持续性疼痛。突破性疼痛的治疗是具有挑战性的现象。口服透粘膜柠檬酸芬太尼(Actiq,Cephalon,Inc,West Chester,PA)是一种新型阿片制剂,具有独特的给药系统,反映了突破性疼痛的特征(起效快且持续时间短),使其成为有效的癌症治疗方法已经接受阿片类药物并经历过耀斑的患者。这篇综述文章旨在介绍口服透粘膜柠檬酸芬太尼在治疗癌症患者突破性疼痛中的作用。特别是,将讨论这种新型药物的合成,临床药理学,药代动力学和药效学性质,毒性和临床功效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号